Short Interest in Lantheus Holdings Inc (NASDAQ:LNTH) Drops By 8.2%

Lantheus Holdings Inc (NASDAQ:LNTH) saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 2,460,000 shares, a drop of 8.2% from the April 30th total of 2,680,000 shares. Based on an average daily trading volume, of 445,400 shares, the days-to-cover ratio is presently 5.5 days. Approximately 6.4% of the shares of the stock are short sold.

In related news, SVP Michael P. Duffy sold 7,198 shares of Lantheus stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $13.13, for a total value of $94,509.74. Following the completion of the sale, the senior vice president now directly owns 133,402 shares in the company, valued at $1,751,568.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Mary Anne Heino sold 9,898 shares of Lantheus stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.06, for a total value of $158,961.88. Following the completion of the sale, the chief executive officer now owns 556,014 shares of the company’s stock, valued at $8,929,584.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,785 shares of company stock valued at $904,824. 2.08% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Lantheus by 99.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,438 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,716 shares during the period. Meeder Asset Management Inc. grew its position in shares of Lantheus by 802.0% in the 4th quarter. Meeder Asset Management Inc. now owns 2,652 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 2,358 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Lantheus in the 4th quarter valued at approximately $57,000. Aigen Investment Management LP bought a new stake in Lantheus in the 4th quarter valued at approximately $67,000. Finally, Pacer Advisors Inc. bought a new stake in Lantheus in the 1st quarter valued at approximately $75,000. Institutional investors and hedge funds own 95.34% of the company’s stock.

Shares of LNTH traded up $0.06 on Friday, hitting $12.70. The company’s stock had a trading volume of 167,995 shares, compared to its average volume of 318,262. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 1.53. The firm’s fifty day moving average price is $12.61 and its 200-day moving average price is $16.63. Lantheus has a fifty-two week low of $8.67 and a fifty-two week high of $29.80. The firm has a market capitalization of $502.52 million, a price-to-earnings ratio of 10.11 and a beta of 1.28.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.07. Lantheus had a return on equity of 46.94% and a net margin of 7.13%. The business had revenue of $90.70 million during the quarter, compared to analyst estimates of $91.70 million. During the same period in the previous year, the firm earned $0.28 EPS. Lantheus’s quarterly revenue was up 4.9% compared to the same quarter last year.

A number of brokerages recently commented on LNTH. BidaskClub lowered Lantheus from a “hold” rating to a “sell” rating in a research report on Friday, May 15th. ValuEngine upgraded Lantheus from a “sell” rating to a “hold” rating in a research report on Saturday, February 15th.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

See Also: What is the FTSE 100 index?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.